DelveInsight’s, “Oncolytic Virus Competitive Landscape 2023” report provides comprehensive insights about 150+ Oncolytic Virus Companies and 175+ drugs in the Oncolytic Virus Competitive landscape. It covers the Oncolytic Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Oncolytic Virus Competitive Landscape Report

• DelveInsight’s Oncolytic Virus report depicts a robust space with 150+ Oncolytic Virus companies working to develop 175+ pipeline therapies for Oncolytic Virus treatment.
• The leading Oncolytic Virus Companies working in the market include Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics, and others.
• Promising Oncolytic Virus therapies in the various stages of development include ASP9801, Pembrolizumab, Recombinant oncolytic herpes simplex virus type 1 (R130), Valacyclovir, CF33-hNIS, and others.
• December 2023: Shanghai Yunying Medical Technology announced a study of early phase 1 clinical trials for Recombinant oncolytic herpes simplex virus TypeⅠ(R130). 9 participants are expected to be enrolled for this open Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus, R130 in patients with advanced bone and soft tissue tumors.
• December 2023: TILT Bio Therapeutics Ltd announced a study of Phase 1 clinical trials for TIL-123 and Pembrolizumab. This is an open-label, phase 1, dose-escalation, multicenter, and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with platinum-resistant or refractory ovarian cancer.
• December 2023: Genelux Corporation announced a study of Phase 3 clinical trials for Bevacizumab (or Biosimilar). The OnPrime study is a multicenter, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with platinum-doublet chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer).

 

Request a sample and discover the recent advances in Oncolytic Virus Drugs @ Oncolytic Virus Competitive Landscape Report

 

The Oncolytic Virus report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Oncolytic Virus report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

 

Oncolytic Virus Overview

Oncolytic viruses (OVs) are organisms able to identify, infect, and lyse different cells in the tumor environment, aiming to stabilize and decrease the tumor progression. They are able to infect abnormal cells through specific targets, such as nuclear transcription factors and among them human telomerase reverse transcriptase, prostate specific antigen, cyclooxygenase-2, osteocalcin, and surface markers as prostate-specific membrane antigen, folate receptor, CD20, endothelial growth factor receptor, and Her2/neu, which are substances produced by the tumor cells.

 

Find out more about Oncolytic Virus Analytical Perspective: In-depth Commercial Assessment @ Oncolytic Virus Collaboration Analysis by Companies

 

Oncolytic Virus Companies and Therapies

• SillaJen Inc.: Pexa-Vec
• Candel Therapeutics: CAN-2409
• CG Oncology: CG0070
• Virogin Biotech: VG161
• Daiichi Sankyo: Teserpaturev

 

Oncolytic Virus Clinical Assessment of Products

The Oncolytic Virus Competitive Landscape report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type.

 

Oncolytic Virus Report Assessment

• Oncolytic Virus Company Analysis
• Oncolytic Virus Therapeutic Assessment
• Oncolytic Virus Pipeline Assessment
• Inactive Oncolytic Virus Drugs Assessment
• Oncolytic Virus Unmet Needs

 

Learn more about the emerging Oncolytic Virus Competitive Landscape @ Oncolytic Virus Market Drivers and Barriers, Unmet Needs

 

Scope of the Oncolytic Virus Competitive Landscape Report

• Coverage- Global
• Oncolytic Virus Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics, and others.
• Oncolytic Virus therapies- ASP9801, Pembrolizumab, Recombinant oncolytic herpes simplex virus type 1 (R130), Valacyclovir, CF33-hNIS, and others.
• Oncolytic Virus Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Oncolytic Virus Product Developmental Activities, Visit @ Oncolytic Virus Research and Development Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Oncolytic Virus: Overview
4. Oncolytic Virus Pipeline Therapeutics
5. Oncolytic Virus Therapeutic Assessment
6. Oncolytic Virus – DelveInsight’s Analytical Perspective
7. SillaJen, Inc.
8. Pexa-Vec: SillaJen, Inc.
9. Drug profiles in the detailed report…..
10. Candel Therapeutics
11. CAN-2409: Candel Therapeutics
12. Drug profiles in the detailed report…..
13. CG Oncology
14. CG0070: CG Oncology
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Oncolytic Virus Key Companies
18. Oncolytic Virus Key Products
19. Oncolytic Virus Unmet Needs
20. Oncolytic Virus Market Drivers and Barriers
21. Oncolytic Virus Future Perspectives and Conclusion
22. Oncolytic Virus Analyst Views
23. Oncolytic Virus Key Companies
24. Appendix

 

For further information on the Oncolytic Virus Report @ Oncolytic Virus Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market